These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 16321834

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
    Jabr FI.
    Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.
    Wu Y, Jia Y, Xu J, Shuai X, Wu Y.
    J Clin Pharm Ther; 2013 Jun; 38(3):249-53. PubMed ID: 23506410
    [Abstract] [Full Text] [Related]

  • 7. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T, Miyazawa K, Okabe S, Kawakubo K, Shimamoto T, Kuriyama Y, Ito Y, Kimura Y, Ohyashiki K, Serizawa H, Iwaya K, Mukai K.
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [Abstract] [Full Text] [Related]

  • 8. Rituximab-induced tumor progression: does it really happen?
    Ozguroglu M, Turna H.
    Med Oncol; 2004 Oct; 21(2):205-6. PubMed ID: 15299193
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
    Culić S, Culić V, Armanda V, Kuljis D, Pesutić-Pisac V, Janković S.
    Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
    [Abstract] [Full Text] [Related]

  • 12. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA, Samad A, Raheem A, Hirani SI, Shabbir- Moosajee M.
    Asian Pac J Cancer Prev; 2018 Feb 26; 19(2):331-335. PubMed ID: 29479962
    [Abstract] [Full Text] [Related]

  • 13. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
    Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA.
    J Clin Oncol; 1999 Mar 26; 17(3):791-5. PubMed ID: 10071268
    [Abstract] [Full Text] [Related]

  • 14. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.
    Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B, Groupe d'Etude des Lymphomes de l'Adulte.
    Hematol J; 2001 Mar 26; 2(6):378-84. PubMed ID: 11920277
    [Abstract] [Full Text] [Related]

  • 15. Complement activation plays a key role in the side-effects of rituximab treatment.
    van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MH.
    Br J Haematol; 2001 Dec 26; 115(4):807-11. PubMed ID: 11843813
    [Abstract] [Full Text] [Related]

  • 16. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
    Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C.
    Blood; 2002 Jan 01; 99(1):67-74. PubMed ID: 11756154
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
    Qiu H, Li J, Feng Z, Yuan J, Lu J, Hu X, Gao L, Lv S, Yang J, Chen L.
    Clin Exp Pharmacol Physiol; 2016 Sep 01; 43(9):795-801. PubMed ID: 27247195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.